Archived Press Releases
Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis
August 7, 2024
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling.
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board
May 6, 2024
Mediar Therapeutics, Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced that, following FDA clearance of its investigational new drug (IND) application, the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-463.